This Market Spotlight report covers the basal cell carcinoma market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, patent information, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
- The approved drugs in the basal cell carcinoma space include Aldara (imoquimod), Erivedge (vismodegib), and Odomzo (sonidegib), which target the immune system and Hedgehog signaling pathway. These therapies are administered via the oral and topical routes.
- The majority of industry-sponsored drugs in active clinical development for basal cell carcinoma are in Phase II. Therapies in the pipeline for basal cell carcinoma focus on a wide variety of targets. These pipeline drugs are administered via the topical, oral, intravenous, and intratumoral routes.
- High-impact upcoming events in the basal cell carcinoma space include topline Phase II trial results for cemiplimab, and a preNDA meeting with the FDA for SUBA-itraconazole.
- There were six licensing and asset acquisition activities involving basal cell carcinoma drugs during 2013-18. The largest deal during this time was the December 2016 $175m agreement between Sun Pharmaceutical and Novartis, for the acquisition of Novartis’s branded oncology product, Odomzo, by Sun Pharmaceutical.
- Erivedge sales ranked highest in the basal cell carcinoma space during 2012-16, and the revenues are expected to remain high through the forecast period (2017-22).
- The clinical trials distribution across Phase I-IV indicates that the majority of trials for basal cell carcinoma have been in early and mid-phases of development, with 80% of trials in Phase I-II, and only 20% in Phase III-IV.
- The US has a substantial lead in the number of basal cell carcinoma clinical trials globally, while Germany leads the major EU markets.
- Clinical trial activity in the basal cell carcinoma space is dominated by completed trials. Valeant Pharmaceuticals has the highest number of completed clinical trials for basal cell carcinoma, with 14 trials.
- Roche leads industry sponsors with the highest number of clinical trials for basal cell carcinoma, followed by Novartis and Valeant Pharmaceuticals.
Basal cell carcinoma subtypes
Electrodesiccation and curettage (ED&C)
Mohs micrographic surgery
Photodynamic therapy (PDT)
Recent incidence studies
Approvals by country
KEY UPCOMING EVENTS
LICENSING AND ASSET ACQUISITION DEALS
Sun Acquires Novartis Cancer Drug In Specialty Push
CLINICAL TRIAL LANDSCAPE
Sponsors by status
Sponsors by phase
List of Figures
Figure 1: Overview of pipeline drugs for basal cell carcinoma in the US
Figure 2: Pipeline drugs for basal cell carcinoma, by company
Figure 3: Pipeline drugs for basal cell carcinoma, by drug type
Figure 4: Pipeline drugs for basal cell carcinoma, by classifications
Figure 5: Key upcoming events in basal cell carcinoma
Figure 6: Licensing and asset acquisition deals in basal cell carcinoma, 2013-18
Figure 7: Parent patents in basal cell carcinoma
Figure 8: Clinical trials in basal cell carcinoma
Figure 9: Top 10 drugs for clinical trials in basal cell carcinoma
Figure 10: Top 10 companies for clinical trials in basal cell carcinoma
Figure 11: Trial locations in basal cell carcinoma
Figure 12: Basal cell carcinoma trials status
Figure 13: Basal cell carcinoma trials sponsors, by phase
List of Tables
Table 1: Marketed drugs for basal cell carcinoma
Table 2: Approvals by country for basal cell carcinoma
Table 3: Pipeline drugs for basal cell carcinoma in the US
Table 4: Historical global sales, by drug ($m), 2012-16
Table 5: Forecasted global sales, by drug ($m), 2017-22